Merz Therapeutics

Focus: Merz Therapeutics is a specialty biotech focused on small-molecule therapeutics across neurology, metabolic diseases, cardiovascular, and infectious disease indications. The company operates from Raleigh, NC with a heavily concentrated revenue base in neurology.

Neurology Metabolic Diseases Cardiovascular Infectious Diseases

Profile data last refreshed 20h ago · AI intelligence enriched 3w ago

Open Jobs

Should You Work at Merz Therapeutics?

AI assessment

Suitable for risk-tolerant professionals seeking stable neurology focus, but approaching patent cliff and minimal hiring suggest career growth constraints.

Why Work Here

Established commercial presence with $44M annual Part D revenue from AMPYRA provides operational stability and proven market execution capability.
Multi-indication pipeline targeting high-unmet-need areas (migraine, neuropathic pain, spasticity) with Phase 3 programs currently advancing.

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

AMPYRA

Multiple sclerosis mobility

$44M Part D

LOE Approaching

Flagship product generating 59% of revenue but facing imminent loss-of-exclusivity, creating urgent need for pipeline replacement.

Help build intelligence for Merz Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified product portfolio across small molecules and biologics (Xeomin, Inbrija, CUVPOSA) reduces single-product dependency and creates cross-functional career opportunities.

Watch Out For

Severe revenue concentration risk: 59% dependence on AMPYRA with loss-of-exclusivity approaching, threatening financial stability and headcount.
Minimal hiring activity (only 3 open roles) signals organizational contraction or stagnation, limiting upward mobility and new opportunity creation.
Limited pipeline quality: only 6 total programs with modest Phase 2/3 activity (1 Phase 2, 2 Phase 3) suggests low innovation velocity and weak near-term catalysts.

Generated by Claude from Merz Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

INBRIJA

Parkinson's disease motor fluctuations

$27M Part D

Peak7.2yr

Second-largest revenue driver with extended exclusivity through 2033, providing multi-year revenue stability in neurology.

Xeomin

Multiple indications (migraine, dystonia, spasticity)

$3M Part D

LOE Approaching

Mature botulinum toxin with Phase 3 programs in chronic and episodic migraine, but minimal current revenue reflects niche positioning.

CUVPOSA

Chronic severe drooling in pediatric neurologic patients (ages 3-16)

$267K Part D

LOE Approaching

Ultra-niche pediatric indication with minimal revenue contribution, representing portfolio tail rather than growth driver.

ERYMAX

Chlamydial and other bacterial infections

Post-LOE

Post-LOE generic antibiotic with no measurable Part D spending, indicating end-stage portfolio position.

Pipeline & Clinical Trials

Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Too

Post-stroke Spasticity

N/A

Clinical Trials (1)

NCT06381999Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Tool

N/A

Pantovigar® vegan

Diffuse Hair Loss in Females

N/A

Clinical Trials (1)

NCT05943860Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss

N/A

CC BoNT/A

Cervical Dystonia

N/A

Clinical Trials (1)

NCT05884528Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia

N/A

IncobotulinumtoxinA

Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury

Phase 2

Clinical Trials (1)

NCT06091020A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury

Phase 2

Xeomin

Chronic Migraine

Phase 3

Clinical Trials (1)

NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Phase 3

Xeomin

Episodic Migraine

Phase 3

Clinical Trials (1)

NCT07018700A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Phase 3

Interview Prep Quick Facts

Portfolio: 5 approved products, 6 clinical trials

Top TAs: Neurology, Cardiovascular, Infectious Diseases

Open Roles: 3 active jobs

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Peak1 (20%)

LOE Approaching3 (60%)

Post-LOE1 (20%)

5 total products

Therapeutic Area Focus

3 marketed4 pipeline

2 marketed

1 marketed

1 marketed

1 marketed

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Merz Therapeutics

Should You Work at Merz Therapeutics?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (4)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (3)

Social Media (Werkstudent)

Initiativbewerbung (Festanstellung)

HR Assistant

Hiring Trend